search
Back to results

Effect of Lifestyle Changes on BDNF Level After Stroke

Primary Purpose

Stroke

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Wellness in Rehabilitation program
Sponsored by
VA Palo Alto Health Care System
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke focused on measuring brain-derived neurotrophic factor, exercise, BDNF, lifestyle medicine

Eligibility Criteria

30 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • History of prior stroke (ischemic or hemorrhagic) or transient ischemic attack
  • Ability to ambulate at least 10 feet with minimal to moderate assistance
  • Ability to travel to intervention site on a weekly basis.

Exclusion Criteria:

  • Cerebral aneurysm
  • Concurrent pregnancy
  • Serious terminal illnesses (e.g. end stage renal disease, heart failure (class IV), cirrhosis (class C), metastatic cancer)
  • Any injury or illness preventing participation in regular aerobic exercise
  • Moderate-severe dementia or cognitive decline

Sites / Locations

  • VA Palo Alto Health Care SystemRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Post-stroke

Arm Description

Patients will receive a 12-week lifestyle medicine program.

Outcomes

Primary Outcome Measures

BDNF level - Final
Plasma BDNF protein levels, expressed in nanograms per milliliter, measured prior to any exercise upon completion of intervention.

Secondary Outcome Measures

BDNF level - Post-exercise
Plasma BDNF protein levels, expressed in nanograms per milliliter, measured immediately following bout of aerobic exercise.
BDNF Genotype
Genotyping of venous blood samples to determine ValVal, MetMet, and ValMet distribution.
Cardiovascular Fitness - VO2 max
Measured as VO2 max (ml/kg/min).
Cardiovascular Fitness - METs
Measured as estimated metabolic equivalents (kcal/kg/hour).
6-minute Walk Test
Total distance walked 6 minutes on a flat surface.

Full Information

First Posted
September 27, 2018
Last Updated
October 8, 2018
Sponsor
VA Palo Alto Health Care System
Collaborators
Stanford University, Spaulding Rehabilitation Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03701815
Brief Title
Effect of Lifestyle Changes on BDNF Level After Stroke
Official Title
Assessing the Effect of Multi-disciplinary Lifestyle Medicine Intervention on Brain-derived Neurotrophic Factor Levels Following Stroke
Study Type
Interventional

2. Study Status

Record Verification Date
October 2018
Overall Recruitment Status
Unknown status
Study Start Date
January 19, 2018 (Actual)
Primary Completion Date
January 11, 2019 (Anticipated)
Study Completion Date
February 28, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
VA Palo Alto Health Care System
Collaborators
Stanford University, Spaulding Rehabilitation Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a pilot study to determine whether a lifestyle medicine intervention following stroke may increase levels of Brain-Derived Neurotrophic Factor (BDNF).
Detailed Description
This is a substudy of the study entitled "Assessing a Multi-Disciplinary Lifestyle Medicine Intervention Following Stroke," specifically looking at the effects of lifestyle change on brain-derived neurotrophic factor (BDNF). BDNF has emerged as a key facilitator of neuroplasticity to improve motor learning and rehabilitation after stroke. Aerobic exercise has been shown to increase levels of BDNF in multiple parts of the central nervous system and therefore may facilitate neuroplasticity and motor recovery. While BDNF levels appear to be increased for up to 1 hour following a bout of aerobic exercise, it is unclear whether regular aerobic exercise over weeks to months can increase baseline BDNF levels in humans following stroke. An single nucleotide polymorphism exists on the BDNF gene in 30-50% of the human population that results in an amino acid change from valine (val) to methionine (met) at position 66 (val66met) of the precursor peptide proBDNF. The presence of the met allele results in a 25% reduction in activity-dependent secretion of BDNF in the CNS. The Wellness in Rehabilitation program at the VA Palo Alto Health Care System is a lifestyle medicine intervention for patients following stroke. It is a 12-week program involving weekly meetings that include exercise (particularly aerobic exercise), nutrition, stress management, education, and group support. Participants are encouraged to perform healthy lifestyle behaviors (i.e. exercise) daily at home, and a health coach calls each patient weekly to support the behavior change process. Participants in the Wellness in Rehabilitation program who elect to participate in the research study will have blood drawn at baseline, week 6, and week 12. Blood draws will be performed in the morning prior to exercise, and week 6 will additionally include a blood draw within 30 minutes of completing a bout of aerobic exercise. Following completion of the study, plasma BDNF levels (measured as nanograms per milliliter) will then be measured at all 4 time points (baseline, week 6 pre-exercise, week 6 post-exercise, and week 12). In addition, BDNF genotype will be measured using the baseline sample. Participants will also complete bike or treadmill exercise testing at baseline and week 12 to determine pre- and post-program cardiovascular fitness levels (measured as VO2 max and estimated metabolic equivalents), and will also complete a 6-minute walk test. They will be asked to record their exercise daily and will additionally complete the Physical Activity Scale for Individuals with Physical Disabilities at baseline and week 12 time points.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke
Keywords
brain-derived neurotrophic factor, exercise, BDNF, lifestyle medicine

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Post-stroke
Arm Type
Experimental
Arm Description
Patients will receive a 12-week lifestyle medicine program.
Intervention Type
Behavioral
Intervention Name(s)
Wellness in Rehabilitation program
Other Intervention Name(s)
Lifestyle Medicine program
Intervention Description
The 12-week Wellness in Rehabilitation program includes weekly in-person meetings including aerobic exercise, nutrition/cooking training, stress management techniques, education, and group support. A health coach will facilitate continuation of healthy behaviors at home.
Primary Outcome Measure Information:
Title
BDNF level - Final
Description
Plasma BDNF protein levels, expressed in nanograms per milliliter, measured prior to any exercise upon completion of intervention.
Time Frame
Week 12
Secondary Outcome Measure Information:
Title
BDNF level - Post-exercise
Description
Plasma BDNF protein levels, expressed in nanograms per milliliter, measured immediately following bout of aerobic exercise.
Time Frame
Week 6
Title
BDNF Genotype
Description
Genotyping of venous blood samples to determine ValVal, MetMet, and ValMet distribution.
Time Frame
Baseline
Title
Cardiovascular Fitness - VO2 max
Description
Measured as VO2 max (ml/kg/min).
Time Frame
Week 12
Title
Cardiovascular Fitness - METs
Description
Measured as estimated metabolic equivalents (kcal/kg/hour).
Time Frame
Week 12
Title
6-minute Walk Test
Description
Total distance walked 6 minutes on a flat surface.
Time Frame
Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: History of prior stroke (ischemic or hemorrhagic) or transient ischemic attack Ability to ambulate at least 10 feet with minimal to moderate assistance Ability to travel to intervention site on a weekly basis. Exclusion Criteria: Cerebral aneurysm Concurrent pregnancy Serious terminal illnesses (e.g. end stage renal disease, heart failure (class IV), cirrhosis (class C), metastatic cancer) Any injury or illness preventing participation in regular aerobic exercise Moderate-severe dementia or cognitive decline
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jeffrey Krauss, MD
Phone
6504935000
Ext
65525
Email
jkrauss@stanford.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Windy McNerney, PhD
Phone
6504935000
Email
windymc@stanford.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey Krauss, MD
Organizational Affiliation
VA Palo Alto Health Care System, Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Palo Alto Health Care System
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeffrey Krauss, MD
Phone
650-493-5000
Ext
65525
Email
jeffrey.krauss@va.gov

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Effect of Lifestyle Changes on BDNF Level After Stroke

We'll reach out to this number within 24 hrs